Journal Mobile Options
Table of Contents
Vol. 85, No. 2, 2013
Issue release date: August 2013
Oncology 2013;85:117-121
(DOI:10.1159/000353138)

Breast Cancer in Systemic Lupus Erythematosus

Tessier Cloutier B. · Clarke A.E. · Ramsey-Goldman R. · Wang Y. · Foulkes W. · Gordon C. · Hansen J.E. · Yelin E. · Urowitz M.B. · Gladman D. · Fortin P.R. · Wallace D.J. · Petri M. · Manzi S. · Ginzler E.M. · Labrecque J. · Edworthy S. · Dooley M.A. · Senécal J.L. · Peschken C.A. · Bae S.C. · Isenberg D. · Rahman A. · Ruiz-Irastorza G. · Hanly J.G. · Jacobsen S. · Nived O. · Witte T. · Criswell L.A. · Barr S.G. · Dreyer L. · Sturfelt G. · Bernatsky S. · Systemic Lupus International Collaborating Clinics (SLICC)
aDivision of Clinical Epidemiology, McGill University Health Centre, Montreal, Que., Canada; bNorthwestern University Feinberg School of Medicine, Chicago, Ill., USA; cLady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Que., Canada; dCollege of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; eDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Conn., and fDepartment of Medicine, University of California, San Francisco, Calif., USA; gService de Rheumatologie, Toronto Western Hospital, Toronto, Ont., and hUniversité de Laval, Quebec, Que., Canada; iCedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, West Hollywood, Calif., jJohns Hopkins University School of Medicine, Baltimore, Md., kWest Penn Allegheny Health System, Allegheny General Hospital, Pittsburgh, Pa., and lDownstate Medical Center, State University of New York, Brooklyn, N.Y., USA; mUniversity of Calgary, Calgary, Alta, Canada; nUniversity of North Carolina at Chapel Hill, Chapel Hill, N.C., USA; oDivision of Rheumatology, University of Montreal Hospital Center, Montreal, Que., and pUniversity of Manitoba, Winnipeg, Man., Canada; qDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea; rDepartment of Rheumatology, Faculty of Medicine, University College London, London, UK; sRheumatic Diseases Research Unit, Department of Medicine, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain; tDalhousie University and Capital Health, Halifax, N.S., Canada; uRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; vLund University Hospital, Lund, Sweden; wHannover Medical School, Medicine, Hannover, Germany; wRosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, Calif., USA;yDepartment of Rheumatology, Rigshospitalet and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Evidence points to a decreased breast cancer risk in systemic lupus erythematosus (SLE). We analyzed data from a large multisite SLE cohort, linked to cancer registries. Methods: Information on age, SLE duration, cancer date, and histology was available. We analyzed information on histological type and performed multivariate logistic regression analyses of histological types according to age, SLE duration, and calendar year. Results: We studied 180 breast cancers in the SLE cohort. Of the 155 cases with histology information, 11 were referred to simply as ‘carcinoma not otherwise specified'. In the remaining 144 breast cancers, the most common histological type was ductal carcinoma (n = 95; 66%) followed by lobular adenocarcinoma (n = 11; 8%), 15 cancers were of mixed histology, and the remaining ones were special types. In our regression analyses, the independent risk factors for lobular versus ductal carcinoma was age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.01-1.14] and for the ‘special' subtypes it was age (OR 1.06, 95% CI 1.01-1.10) and SLE duration (OR 1.05, 95% CI 1.00-1.11). Conclusions: Generally, up to 80% of breast cancers are ductal carcinomas. Though our results are not definitive, in the breast cancers that occur in SLE, there may be a slight decrease in the ductal histological type. In our analyses, age and SLE duration were independent predictors of histological status.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE: Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130-135.
  2. Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93:1046-1052.
  3. Louwman MW, Vriezen M, Van Beek MW, Tutein Noltlienius-Puylaert MC, Van Der Sangen MJ, Roumen RM, Kiemeney LA, Coebergh JW: Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 2007;121:127-135.
  4. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (eds): SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, National Cancer Institute, 2007, SEER Program, NIH Pub No 07-6215.
  5. Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, Schairer C, Engels EA, Pfeiffer RM, Goedert JJ: Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009;100:817-821.
  6. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-5380.
  7. Chavele KM, Ehrenstein MR: Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011;585:3603-3610.
  8. Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM: Targeting cancer with a lupus autoantibody. Sci Transl Med 2012;4:157ra142.
  9. Stratton MR: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-1510.
  10. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, National Cancer Institute. http://seer.cancer.gov/csr/1975_2009_pops09/ (based on November 2011 SEER data submission, posted to the SEER web site April 2012).
  11. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH: Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131:1061-1066.
  12. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R: Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Care Res 2005;53:781-784.
  13. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS: Histopathology of breast cancer in relation to age. Br J Cancer 1997;75:593-596.
  14. Rahim R, Strobl JS: Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009;20:736-745.
  15. Moran EM: Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.

    External Resources

  16. Bernatsky S, Clarke A, Suissa S: Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis. Ann Rheum Dis 2008;67:277-278.
  17. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE: The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis 2008;67:74-79.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50